The assessment of oral-motor behavior (OMB) represents one the earliest noninvasive ways to evaluate newborns' well-being and neuromotor behavior. This work aimed at developing a new low-cost, easy-to ...

The optimal feature is necessary for the reach of electromyography (EMG) control or human-machine interface. This study aimed to find the optimal feature of time-domain features. Five oral muscles ...

These are the best electric toothbrushes you can buy in every category, from Oral-B Genius X and Bitvae R2 to Waterpik ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Review question We wanted to know whether cognitive training interventions are effective in improving cognition (thinking) in people with Parkinson's disease dementia or mild cognitive impairment.

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed ...

The coexistence of coronary artery disease and atrial fibrillation (AF) in the same individuals raises great concern about the co-treatment with different antithrombotic agents in the case of ...

Spinal Muscular Atrophy treatment is evolving fast, with gene therapy, oral drugs, and next-gen muscle enhancers offering new hope and long-term outcomes. With each breakthrough in SMA treatment, we ...

Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 inhibitor, VTX3232, in individuals with ...

An oral therapy with similar efficacy could dramatically expand access and affordability in global markets. Scientifically, these developments mark a milestone: transcription factors, long labeled ...

In patients with Parkinson disease (PD) and comorbid mood dysfunction, psilocybin-assisted therapy is well-tolerated and associated with sustained improvements in depression, anxiety, motor ...

The data was featured as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.